US FDA Neurology Drugs Program Gains Boost In FY 2023 Funding Bill Amid Calls To Clarify Development Policies
Executive Summary
US FDA gains a nearly 7% increase in non-user fee funding, some of which will go for neurology drug guidance.
You may also be interested in...
Will Califf’s Attention To Foods Come At Expense Of US FDA’s Drugs Program?
FDA Commissioner Robert Califf says the medical product programs have received a lot of attention and now it’s the food program’s turn.
Rare Disease Expertise On FDA Advisory Committees Gains Capitol Hill Attention
With Congress watching whether enough experts are on advisory committees for orphan drugs, the US FDA may be pressured into changes.
Advisory Committee Disagreement With US FDA On Approval Decisions An Increasingly Rare Event
A new study finds the agency only approved a product despite a negative advisory committee vote six times in six years. The overall rate of agreement between the agency and advisory committees has increased since 2015.